Drug‐specific T‐cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat
Abstract
Background Atabecestat is an orally administered BACE inhibitor developed to treat Alzheimer's disease. Elevations in hepatic enzymes were detected in a number of in trial patients, which resulted in termination of the drug development programme. Immunohistochemical characterization of liver tissue from an index case of atabecestat‐mediated liver injury revealed an infiltration of T‐lymphocytes in areas of hepatocellular damage. This coupled...
Paper Details
Title
Drug‐specific T‐cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat
Published Date
Nov 24, 2020
Journal
Volume
76
Issue
6
Pages
1825 - 1835
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History